Inform patients of potential worsening of existing tuberculosis, fungal, bacterial, viral, or parasitic infections or ocular herpes simplex.Advise patients that Arnuity Ellipta may cause systemic corticosteroid effects of hypercorticism and adrenal suppression. These patients should also be instructed to carry a warning card indicating that they may need supplementary systemic corticosteroids during periods of stress or a severe asthma attack.Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to Arnuity Ellipta. The mechanism comprises at least one receiving station for receiving each of the plural medicament carriers; a release for releasing in combination a distinct medicament dose portion from each of the plural medicament carriers on receipt thereof by said receiving station; an outlet, positioned to be in communication with the distinct medicament dose portions releasable by said release; and at least one indexer for individually indexing the distinct medicament dose portions of each of the plural medicament carriers. The potential for “catch-up” growth following discontinuation of treatment with orally inhaled corticosteroids has not been adequately studied. Giving Arnuity Ellipta Blister, With Inhalation Device to a child under 12 Severe Precaution: Potential risk of decreased growth velocity. Monitor patients for corticosteroid-related side effects. Corticosteroids have been shown to have a wide range of actions on multiple cell types (e.g., mast cells, eosinophils, neutrophils, macrophages, lymphocytes) and mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines) involved in inflammation. Do not attempt to take the inhaler apart.Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).Inform patients that Arnuity Ellipta is not meant to relieve acute symptoms of asthma and extra doses should not be used for that purpose. During this period of HPA suppression, patients may exhibit signs and symptoms of adrenal insufficiency when exposed to trauma, surgery, or infection (particularly gastroenteritis) or other conditions associated with severe electrolyte loss. Individual patients may experience a variable time to onset and degree of symptom relief.Arnuity Ellipta should be administered as 1 inhalation once daily by the orally inhaled route. Available for Android and iOS devices.Patent use: FOR ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 5 YEARS AND OLDERPatent use: INDICATED FOR THE ONCE-DAILY MAINTENANCE TREATMENT OF ASTHMA AS PROPHYLACTIC THERAPY IN PATIENTS AGED 12 YEARS OF AGE AND OLDER Cannot be used with any insurance benefit or copay assistance programs. The daily dosage of Arnuity Ellipta should not exceed 1 inhalation. In such children or adults who have not had these diseases or been properly immunized, particular care should be taken to avoid exposure. Anti-inflammatory androstane derivative Patent 7,101,866 Issued: September 5, 2006 Inventor(s): Biggadike; Keith & Coote; Steven John & Nice; Rosalyn Kay Assignee(s): Glaxo Group Limited According to one aspect of the invention, there is provided a compound of formula (I) and solvates thereof. (2.2) ----- DOSAGE FORMS AND STRENGTHS----- Write the date you open the tray on the label on the inhaler. 1. The mean age was 46 years. Serious adverse events, whether considered drug-related or not by the investigators, that occurred in more than 1 subject and in a greater percentage of subjects treated with Arnuity Ellipta than placebo included hypertension, abscess, breast cancer, traumatic limb amputation, subarachnoid hemorrhage, and intervertebral disc protrusion; all events occurred at rates ≤1%.The incidence of adverse reactions associated with Arnuity Ellipta 100 mcg is shown in Table 1 and is based on one 24-week trial (Trial 1) in adult and adolescent subjects with asthma.The incidence of adverse reactions associated with Arnuity Ellipta 200 mcg is shown in Table 2 and is based on one 24-week trial (Trial 3) in adult and adolescent subjects with asthma. Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to children and adolescents. Caution should be exercised when considering the coadministration of Arnuity Ellipta with ketoconazole and other known strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin, conivaptan, indinavir, itraconazole, lopinavir, nefazodone, nelfinavir, saquinavir, telithromycin, troleandomycin, voriconazole) There are insufficient data on the use of Arnuity Ellipta in pregnant women. The clinical significance of small changes in BMD with regard to long-term consequences such as fracture is unknown. Monitor the growth of children and adolescents receiving Arnuity Ellipta routinely (e.g., via stadiometry). Concomitant administration of the strong CYP3A4 inhibitor ketoconazole increases the systemic exposure to fluticasone furoate. Mean baseline percent predicted FEVBoth Arnuity Ellipta 200 mcg once daily and fluticasone propionate 500 mcg twice daily produced improvement from baseline in lung function. Keep out of reach of children.Arnuity Ellipta should be stored inside the unopened moisture-protective foil tray and only removed from the tray immediately before initial use. Inside Rx Pets card is only for use with prescriptions written and dispensed for animals at a participating pharmacy.